NCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
Clinical Trials
15 trialsNCT06043323 2026-03-12
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07042438 2026-03-05
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
City of Hope Medical Center
Phase 2 Recruiting
NCT04205838 2026-02-27
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT05757219 2026-02-27
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT03642626 2026-01-23
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT06213311 2026-01-14
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03105336 2025-12-23
ZUMA-5
Gilead Sciences
Phase 2 Completed
NCT07254754 2025-11-28
LATE-R-GEL-23
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
NCT06550141 2025-11-14
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Massachusetts General Hospital
Phase 2 Recruiting
NCT06826118 2025-02-13
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT04432506 2025-01-28
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03761056 2024-12-04
ZUMA-12
Gilead Sciences
Phase 2 Completed